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There are 17 known ubiquitin-like proteins (UBLs) from nine phylogenetically distinct classes (NEDD8, SUMO,
ISG15, FUB1, FAT10, Atg8, Atg12, Urm1, and UFM1) that have been identified to conjugate to substrates in
a manner analogous to ubiquitin. NEDD8 is one of the most studied UBLs and shares the highest amino acid
similarity to ubiquitin. Here, we review the current knowledge of the NEDD8 conjugation cascade derived
from functional studies in genetic model organisms, structural insights from crystallographic studies,
biochemical studies identifying a growing list of NEDD8 substrates with oncogenic implications, and
attempts to pharmacologically target the NEDD8 pathway in cancer.The NEDD8 Conjugation Cascade
In 1992, a subtractive cloning screen between a cDNA library
derived from mouse neural precursor cells and mouse adult
mRNA identified ten neural precursor cell-expressed, develop-
mentally downregulated (NEDD) genes (Kumar et al., 1992).
The eighth gene discovered, NEDD8, shared approximately
60% amino acid identity with ubiquitin and similarly conjugated
to substrates (Kamitani et al., 1997).
Analogous to ubiquitylation, the NEDD8 conjugation cascade
or neddylation involves E1, E2, E3, and deneddylating enzymes
(Figure 1) (Liakopoulos et al., 1998; Osaka et al., 1998). Like ubiq-
uitin, NEDD8 is first synthesized as a precursor that is processed
at the conserved C-terminal Gly76 residue by the hydrolase
activity of deneddylating enzymes exposing a glycine-glycine
motif that serves as the attachment site for target substrates
(Kamitani et al., 1997). NEDD8-specific proteases able to
hydrolyze the NEDD8 C-terminus include NEDP1 (also known
as DEN1 and SENP8) and UCH-L3, which can also process
ubiquitin precursors (for review, see Rabut and Peter, 2008;
Xirodimas, 2008). The exposed C-terminal glycine of NEDD8 is
adenylated by the E1 NEDD8-activating enzyme (NAE), which
is composed of NAE1 (APP-BP1) and Uba3 heterodimer, in an
ATP-dependent reaction and transferred to E1 cysteine side
chain via thiolester linkage (for review, see Pan et al., 2004).
Activated NEDD8 is subsequently transferred to the E2
NEDD8-conjugating enzyme, Ubc12, forming another thiolester
linkage. Ube2f is another NEDD8 E2, which preferentially
promotes neddylation of Cul5 (Huang et al., 2009). An E3
NEDD8 ligase then transfers NEDD8 to the 3-amino group of lysyl
residue on substrates forming an isopeptide bond. NEDD8 E3s
contain really interesting novel gene (RING) finger domains,
which include Rbx1 and Rbx2 (also known as ROC1 and
ROC2, respectively), MDM2, c-CBL, and SCFFBX011 (Abida
et al., 2007; Kamura et al., 1999; Oved et al., 2006; Xirodimas
et al., 2004) with the sole exception being DCN1 (Kurz et al.,
2005, 2008). Interestingly, DCN1 does not require any of its
cysteines for its catalytic activity; rather DCN1 in conjunction
with the yeast Rbx1 homolog, Hrt1, functions synergistically as
a dual NEDD8 E3 ligase to promote ligation to Cdc53 (Scott
et al., 2010). There are five DCN1-like proteins in humans termed168 Cancer Cell 19, February 15, 2011 ª2011 Elsevier Inc.DCNL1-5, of which DCNL1-3 have been shown to promote Cul3
neddylation (Meyer-Schaller et al., 2009).
The types of ubiquitin chains linked to a given substrate play
crucial roles in dictating the functional outcome. However, the
types of NEDD8 chains are only beginning to be elucidated.
Recently, Jones et al. discerned from mass spectrometry anal-
yses that Lys11, Lys22, Lys48, and Lys60 can be linked to
form NEDD8 chains in vivo (Jones et al., 2008). Poly-NEDD8
chain formation is thought to be mediated by a build-up of
NEDD8 on Ubc12 catalytic cysteine prior to transfer to Cul1
(Ohki et al., 2009). NEDD8 can also be linked to ubiquitin chains
in vitro (Whitby et al., 1998). Ubiquitin has also emerged in
proteomic studies identifying NEDD8 substrates, although the
prevalence of such mixed ubiquitin-NEDD8 chains appears
minor and their function is not known (Jones et al., 2008; Xirodi-
mas et al., 2008).
Neddylation is a reversible process. The COP9 signalosome
(CSN) is a zinc metalloprotease and the most studied of the
NEDD8 deconjugating enzymes. CSN is an 8 subunit complex,
where CSN5 subunit possesses the catalytic activity (Lyapina
et al., 2001; Schwechheimer et al., 2001). NEDP1 was recently
identified as another NEDD8-specific protease (Rabut and Peter,
2008; Xirodimas, 2008). However, compared to CSN, NEDP1
exhibits three orders of magnitude less activity in cleaving
neddylated Cul1 (Yamoah et al., 2005). Interestingly, deletion
of NEDP1 ortholog in Schizosaccharomyces pombe and
Drosophila melanogaster did not result in accumulation of ned-
dylated Cul1 or Cul3, although a significant accumulation of
yet-identified neddylated substrates was observed, suggesting
roles for NEDP1 in the regulation of cullin-independent
substrates (Chan et al., 2008; Zhou and Watts, 2005). Additional
proteases with dual NEDD8 and ubiquitin protease activity have
been identified (see Figure 1; for review, see Rabut and Peter,
2008; Xirodimas, 2008).
Structural Insight into the NEDD8 Machinery
E1 activating enzymes for ubiquitin and ubiquitin-like proteins
(UBLs) possess adenylation domain that binds ATP and ubiquitin
or UBL, a catalytic Cys domain possessing the cysteine for
thiolester linkage, and an ubiquitin fold domain (UFD) that binds
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Figure 1. General Overview of the NEDD8 Conjugation Pathway
(1) NEDD8 is synthesized as a precursor that is processed at a conserved C-terminal gly(76) residue by the hydrolase activity of deneddylating enzymes, which
include NEDP1 and UCLH3, exposing a glycine-glycine motif that serves as the attachment site for target substrates. (2) The exposed C-terminal glycine of
NEDD8 is adenylated by an activating (E1) enzyme in conjunction with ATP and transferred to a cysteine side chain of an E1 via a thiolester linkage. (3) Activated
NEDD8 is subsequently transferred to a conjugating (E2) enzyme forming another thiolester linkage. (4) A ligase (E3) transfers NEDD8 to the 3-amino group of
a substrate lysyl residue resulting in the formation of an isopeptide bond. (5) Covalent modification of substrates can be reversed by the action of deneddylating
enzymes, which include CSN, NEDP1, USP21, Ataxin-3, PfUCH54, UCH-L1, and UCH-L3.
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mechanisms governing activation of ubiquitin and subsequent
transfer to an E2 enzyme is best characterized for the ubiquitin
E1, Uba1. In brief, following E1-mediated adenylation of the
ubiquitin C-terminus, the E1 catalytic cysteine attacks the ubiq-
uitin adenylate forming a thiolester intermediate (Ciechanover
et al., 1981, 1982). Uba1 subsequently loads an additional ubiq-
uitinmolecule by catalyzing the adenylation of a second ubiquitin
(Haas and Rose, 1982; Haas et al., 1982). Occupancy of ubiqui-
tin-AMP in the adenylation domain was found to stimulate ubiq-
uitin transthiolation from the E1 to E2 enzymes, demonstrating
the crosstalk between the adenylation active site and the E1-
E2 transfer (Pickart et al., 1994). Finally, structural overlap
between E1 and E3 binding sites found in E2s result in mutually
exclusive E1-E2 and E2-E3 interactions, ensuring progression of
the E1-E2-E3 cascade (Eletr et al., 2005).
Schulman and colleagues have elucidated many of the molec-
ular mechanisms that mediate the E1-E2-E3 cascade reaction
for the NEDD8 pathway, and identified specific molecular deter-
minants that distinguish the ubiquitin and NEDD8 conjugation
cascades (for review, see Schulman and Harper, 2009). First,
Uba1 and the NEDD8 activating enzyme component, Uba3,
differ in their ability to interact with ubiquitin and NEDD8, respec-
tively, due to amino acid dissimilarity at residue 72 (Ala in NEDD8
and Arg in ubiquitin) (Walden et al., 2003). The selectivity is attrib-
uted to a unique Arg in Uba3, which repels Arg72 of ubiquitin.
Second, the selectivity of NEDD8 cascade is also dictated by
interactions of the N-terminal sequence of the E2 catalytic
domain and the UFD of Uba3. A unique 26 amino acid N-terminal
extension of Ubc12 docks in a groove exclusive to Uba3, further
ensuring pathway specific E1-E2 interactions (Huang et al.,
2005a). Interestingly, when the NAE1/Uba3 heterodimer is
doubly loadedwith NEDD8 linked by a thiolester bond and an ad-
enylated NEDD8, the UFD undergoes a striking conformational
change that unmasks a cryptic Ubc12 binding site, and as
a result, promotes E2 binding when the E1 is ready to transferNEDD8 (Huang et al., 2007). Thus, the transfer of NEDD8 to
Ubc12 may eliminate the second binding site, which would
promote Ubc12-NEDD8 dissociation (Schulman and Harper,
2009). Finally, as demonstrated for ubiquitin and SUMO E1 and
E2 enzymes, the NEDD8 E1 and E3 binding sites overlap on
Ubc12, which ensures progression of the E1-E2-E3 cascade
(Huang et al., 2005a).
Biological Roles of NEDD8 from Model Organisms
and Links to Cancer
An intact NEDD8 pathway is required for viability in S. pombe,
D. melanogaster, Caenorhabditis elegans, and mice (for review,
see Pan et al., 2004). Inactivation of the NEDD8 pathway in the
ts41 CHO cell line possessing a temperature-sensitive mutation
in the SMC gene (the hamster ortholog of human NAE1) caused
multiple rounds of S-phase DNA replication without intervening
mitosis (Handeli and Weintraub, 1992; Hirschberg and Marcus,
1982). RNAi-mediated knockdown of NED-8, or NED-8 E1
and E2 enzymes in C. elegans caused hypersensitivity to ENU-
induced apoptosis in germ cells (Gao et al., 2008), and other
developmental abnormalities including defects in cytoskeleton
regulation (Jones and Candido, 2000; Kurz et al., 2002). In the
plant, Arabidopsis thaliana, NEDD8 E2 ortholog RCE1 mutants
had a reduced growth phenotype (Dharmasiri et al., 2003).
A general elevation in the level of NEDD8 conjugation has been
observed in oral squamous cell carcinoma cell lineswhereNEDD8
pathway inhibition decreased cell proliferation (Chairatvit and
Ngamkitidechakul, 2007). The components of cullin-RING ligases
(CRLs) are overexpressed, amplified or mutated in several human
cancers, andmanyCRLs regulate the activity of numerousplayers
in tumorigenesis (see Table 1) (for review, seeGuardavaccaro and
Pagano, 2004). Several newly discovered NEDD8 substrates are
established tumor suppressors or oncoproteins, including VHL,
p53 and MDM2 (Table 1). Furthermore, the general inhibitor of
NEDD8 pathway, MLN4924, was recently shown to possess
tumor-inhibiting properties (Soucy et al., 2009).Cancer Cell 19, February 15, 2011 ª2011 Elsevier Inc. 169
Table 1. NEDD8 Substrates Implicated in Tumorigenesis
Substrates Function of NEDD8 Modification Cancer Implications
Cul1 Increases CRL activity CRL1 or SCF complexes degrade a multitude of substrates. For example,
SCFSkp2 degrades inhibitors of cell cycle progression and is amplified in
a number of human cancers; SCFb-Trcp promotes degradation of the IkB
family of NF-kB inhibitors, and elevated levels of b-Trcp has been reported in
tumors and often associated with poor prognosis; SCFFbw7 complex
primarily mediates degradation of oncoproteins Cyclin E, Notch and c-myc,
and Fbw7 is a bona fide tumor suppressor that is frequently mutated in
human cancer. Notably, more than 350 potential CRL1 substrates have been
identified using global protein stability (GPS) profiling technology.
Cul2 Increases CRL activity Cul2 neddylation required for the tumor suppressor VHL function of
mediating HIFa degradation via the ECV complex.
Cul3 Increases CRL activity CRL3 complexes have roles in regulating cytokinesis, oxidative stress
response pathways, oncogenic Wnt-b-catenin and Hedgehog signaling
pathways.
Cul4 Increases CRL activity CRL4 complexes regulate DNA replication and nucleotide excision repair
(NER), and Cul4A is amplified in breast cancer.
Cul5 Increases CRL activity Adenoviral proteins have been identified that utilize CRL5 complexes to
promote degradation of tumor suppressor proteins to promote propagation
of the infection cycle.
Cul7 — Cul7 possesses an antiapoptotic function through its ability to regulate p53,
and Cul7 is overexpressed in non-small cell lung carcinoma.
PARC — PARC negatively regulates p53 function by promoting cytoplasmic
localization in neuroblastoma cells.
p53/p73/ BCA3/ VHL Regulates transactivation function
and protein-protein interactions
Neddylation regulates transactivation function of the p53 family, the ability of
BCA3 to regulate NF-kB, and the regulation pVHL-fibronectin interaction.
MDM2, L11 Increases protein stability MDM2 and L11 stability is regulated by NEDD8.
EGFR Increases receptor lysosomal sorting c-Cbl mediates EGFR endocyctosis by promoting ubiquitylation and
neddylation of EGFR, and c-Cbl mutations are observed in a number of
human cancers.
See text for details.
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The cullin family is composed of Cul1, 2, 3, 4A, 4B, 5, and 7, and
PARC and Apc2, a component of the anaphase promoting
complex/cyclosome (APC/C), contain a cullin homology domain
(for review, see Petroski and Deshaies, 2005). The first and best-
characterized NEDD8 substrates are the cullins, which are
structurally related proteins that function as molecular scaffolds
of CRLs. PARC is also subject to neddylation, but Apc2, which
lacks the purported C-terminal NEDD8 consensus sequence
(IVRIMKMR) found in cullins, is not (Pan et al., 2004; Skaar
et al., 2007). CRLs are composed of RING finger protein Rbx1
or Rbx2, a substrate recognition subunit that binds directly or
via an adaptor protein to the N-terminus of cullins (Figure 2).
Rbx1 and Rbx2 in conjunction with Ubc12 and Ube2f, respec-
tively, promote NEDD8 modification of cullins (Huang et al.,
2009; Kamura et al., 1999). Cullin neddylation has been shown
to increase the ubiquitylation activity of CRLs. For example,
Cul1 neddylation increased SCF-mediated degradation of IkBa
and p27 (for review, see Pan et al., 2004). Cullin neddylation
promotes conformational changes that increase binding of
Rbx1 to ubiquitin E2s, reduce the distance between E2 and the
substrate recognition component, thus bringing ubiquitin closer
to its target, and increase ubiquitin chain extension by allowing
greater E2 access to the nascent polyubiquitin chain (Duda170 Cancer Cell 19, February 15, 2011 ª2011 Elsevier Inc.et al., 2008; Pan et al., 2004; Saha and Deshaies, 2008; Yamoah
et al., 2008). Neddylation also abrogates binding of CAND1,
which associates with unneddylated cullins to inhibit CRL
activity by preventing cullin binding to adaptor and substrate
recognition components (Liu et al., 2002; Zheng et al., 2002).
CSN-mediated deneddylation has the reverse effect of acti-
vating CRL-based E3s, and the CSN also recruits the deubiqui-
tinating enzyme Ubp12/USP15 to prevent ubiquitin chain
assembly by CRLs (Lyapina et al., 2001; Schwechheimer et al.,
2001; Zhou et al., 2003). However, dynamic cycling of NEDD8
conjugation and deconjugation are critical in maintaining CRL
activity, as deletion of any CSN subunit or CAND1 leads to
decreased CRL function (for review, see Petroski and Deshaies,
2005). Recently, Wolf and colleagues demonstrated that only
a subset of F-box proteins (FBP) requires CSN for protection
against autocatalytic destruction, and CAND1 does not play
a role in the regulation of adaptor stability but regulates FBP
complex formation. Upon substrate-induced neddylation,
CRLs are subjected to regulation by CSN. Following substrate
degradation, CSN deneddylates cullin to permit CAND1 regula-
tion of CRL (Schmidt et al., 2009). Through the use of general
NAE inhibitor MLN4924 and a quantitative mass spectrometry
based methodology, Harper and colleagues recently demon-
strated that prolonged global dennedylation does not convert
CRL complexes to cullin-CAND1 complexes (Bennett et al.,
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Figure 2. The Cullin RING Finger E3 Ligase Complexes
The best characterized cullin RING ligase (CRL) is the Skp1-Cul1-F-box
protein (SCF) complex, where Cul1 functions as a scaffolding protein in which
its N-terminus interacts with the adaptor subunit, Skp1, and its C terminus with
the Rbx1 RING finger protein that associates with an E2 ubiquitin conjugating
enzyme to promote substrate ubiquitylation. Skp1 interacts with an F-box
protein (FBP) substrate recognition component of the SCF. Both Cul2
and Cul5 interact with Elongin B and C adaptor proteins and Rbx1 or Rbx2,
respectively. Cul2 and Cul5 associate with VHL and suppressor of cytokine
signaling (SOCS) box protein, respectively, that function as the substrate
recognition subunit. Cul3 interacts with Rbx1and broad complex, Tramtrack
and Bric-a-Brac (BTB) protein that mediates both substrate specificity and
binding to Cul3. Cul4 interacts with Rbx1 and the damaged DNA binding
(DDB1) adaptor protein, and a DDB1 and Cul4-associated factor (DCAF)
substrate recognition protein. There are approximately 110 F-box proteins,
50 SOCS/BC box proteins, 450 BTB, and 90 DCAF known or predicted human
proteins, and as a result, a multitude of CRLs can be potentially assembled
from the 7 human cullin family members to target a myriad of substrates for
degradation (for review, see Jackson and Xiong, 2009 and Petroski and
Deshaies, 2005).
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status, most cullins are bound to adaptors whereas a small frac-
tion is associatedwith CAND1, suggesting that the abundance of
adaptor modules, rather than cycles of neddylation and CAND1
binding, drives global CRL network organization (Bennett et al.,
2010).
Neish and colleagues discovered enteric bacteria-induced
ROS production from colonized epithelial cells inactivates
the catalytic cysteine residue of Ubc12 resulting in decreased
Cul1 neddylation and inhibition of the NF-kB pathway due to
stabilization of the SCFb-Trcp substrate and NF-kB inhibitor,
IkB-a (Collier-Hyams et al., 2005; Kumar et al., 2007). A recent
study identified an additional mechanism of bacteria-induced
inhibition of ubiquitin/NEDD8 conjugation via the bacterial
effector deamidase, CHBP, which promotes deamidation of
Gln40 of NEDD8, resulting in abolishment of CRL activity (Cui
et al., 2010).
Cul1-Based CRLs
The three most studied Cul1-CRLs (CRL1) or Skp1-Cul1-F-box
protein (SCF) complexes with cancer implications are SCFSkp2,
SCFb-Trcp, and SCFFbw7. SCFSkp2 degrades inhibitors of cell
cycle progression p130 (retinoblastoma-related ‘‘pocket
protein’’) and the cyclin-dependent kinase (CDK) inhibitors
p27Kip1, p57Kip2, and p21Cip1 (for review, see Guardavaccaro
and Pagano, 2004). Tumor suppressor BRCA2, TOB1, FOXO1,
and RASSF1A have also been identified as SCFSkp2 substrates(Hiramatsu et al., 2006; Huang et al., 2005b; Moro et al., 2006;
Song et al., 2008). SCFb-Trcp promotes degradation of IkB family
of NF-kB inhibitors and pro-apoptotic BH3-only tumor
suppressor protein, BimEL (Dehan et al., 2009; Guardavaccaro
and Pagano, 2004). In addition, overexpression of b-Trcp in the
mammary epithelia of female mice promotes the development
of carcinomas in approximately 40% of these mice (Kudo
et al., 2004). Conversely, SCFFbw7 primarily mediates degrada-
tion of Cyclin E, Notch and c-myc oncoproteins (for review,
see Guardavaccaro and Pagano, 2004). Fbw7 is located on
chromosome 4q32 where genetic aberrations are frequent and
Fbw7 mutations have been detected in human cancer (for
review, see Welcker and Clurman, 2008). Studies from a number
of model organisms have demonstrated roles for Fbw7 in the
negative regulation of cell cycle, development and tumorigen-
esis (Matsuoka et al., 2008; Moberg et al., 2001; Tetzlaff et al.,
2004). Thus, Cul1 assembles CRLs that have tumor suppressor
or oncogene functions depending on the respective substrate
recognition components. Notably, there are approximately 110
F-box proteins and as a result a number of SCF complexes
can be formed to regulate a plethora of substrates (Petroski
and Deshaies, 2005). Recently, Elledge and colleagues applied
global protein stability (GPS) profiling technology and identified
more than 350 potential CRL1 substrates, highlighting the impor-
tance of cullin-mediated regulation in a broad range of cellular
functions (Yen and Elledge, 2008).
Cul2-based CRL, ECV
Cul2 forms a CRL2 complex with the tumor suppressor von
Hippel-Lindau (VHL) protein, germline mutation of which causes
VHL disease characterized by the development of multiple
tumors in numerous organs upon the loss of the remaining
wild-type allele in a susceptible cell. Biallelic inactivation of
VHL is also responsible for the development of the vast majority
of sporadic clear-cell renal cell carcinomas (RCC), the most
common form of kidney cancer (for review, see Kaelin and Rat-
cliffe, 2008).
VHL is the substrate-recognition component of CRL2 called
ECV (Elongin BC/Cul2/VHL), which targets hypoxia-inducible
factor a subunit (HIFa) in an oxygen-dependent manner (Kaelin
and Ratcliffe, 2008). Similar to Cul1, Cul2 neddylation increases
E3 function of ECV (Ohh et al., 2002). Unexpectedly, VHL was
identified as the first tumor suppressor targeted for neddylation
and thereby expanding the substrate repertoire of NEDD8
beyond cullins (Stickle et al., 2004). VHL neddylation prohibited
the engagement of Cul2 while promoting VHL association with
fibronectin, which was necessary for the tumor suppressor
activity of VHL (Russell and Ohh, 2008).
Cul3-Based CRLs
Cul3-CRL complexes (CRL3s) have been implicated in
the degradation of Cyclin E (Singer et al., 1999). Studies from
C. elegans showed that Cul3 interacts with several BTB protein
subunits, including Mel-26 that targets Mei-1, an essential
component of the mitotic spindle, for degradation (Furukawa
et al., 2003; Geyer et al., 2003; Kurz et al., 2002; Pintard et al.,
2003; Xu et al., 2003). Furthermore, BTB subunits KLHL9-
KLHL13 form a complex with Cul3 to remove Aurora B from
mitototic chromosomes promoting completion of cytokinesis in
human cells (Sumara et al., 2007). In Drosophila, Cul3 regulates
the stability of Cubitus interuptus (Ci), which is a known regulatorCancer Cell 19, February 15, 2011 ª2011 Elsevier Inc. 171
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KLHL12-Cul3 negatively regulates Dishevelled, which is often
overexpressed in non-small cell lung cancer and is a positive
regulator of the oncogenic Wnt-b-catenin pathway (Angers
et al., 2006; Uematsu et al., 2003). CRL3s are also known to
regulate oxidative stress response pathways. The BTB subunit
KEAP1 (also known as INRF2) interacts with Cul3 to promote
the degradation of the transcription factor, NRF2 (for review,
see Niture et al., 2010). Following the generation of reactive
oxygen species (ROS) in response to a number of stress-
inducing agents, NRF2 dissociates from KEAP1 to transactivate
genes possessing an antioxidant response element (ARE) that
protect against oxidative stress. Therefore, NRF2 plays a role
in protecting against DNA damaging agents as demonstrated
from Nrf2 null mice that have increased incidence of carcin-
ogen-induced tumors (Niture et al., 2010). However, somatic
mutations of KEAP1 and NRF2 have been observed in a number
of cancers that allow NRF2 to escape KEAP1-mediated regula-
tion resulting in NRF2-mediated constitutive induction of cyto-
protective enzymes that provide cancer cells with a survival
advantage to anticancer treatments (Shibata et al., 2008).
Cul4-Based CRLs
Cul4A and Cul4B are two closely related paralogs in mammals.
DDB1-Cul4CDT2 promotes degradation ofC. elegans polymerase
h, Drosophila E2F1, human p21, and the replication factor CDT1
that is degraded during S-phase and in response to DNA
damage (for review, see Jackson and Xiong, 2009). RNAi-medi-
ated inactivation of cul-4 in C. elegans results in cell proliferation
accompanied by massive levels of DNA re-replication, which is
rescued by reduction of CDT-1 levels (Zhong et al., 2003). Muta-
tions in the DCAF protein DDB2 are responsible for the heritable
human disorder Xeroderma pigmentosum (XP) subtype E
phenotype, which is characterized by defects in nucleotide exci-
sion repair (NER) and susceptibility to skin cancer (Chu and
Chang, 1988). DDB1-Cul4DDB2 mediates monoubiquitylation of
core histones H2A, H3 and H4, which are thought to initiate
NER (Kapetanaki et al., 2006). DDB1-Cul4DDB2 also regulates
polyubiquitylation of the NER protein, XPC, which is thought to
promote its DNA binding affinity (Sugasawa et al., 2005) and
DDB2 itself is negatively regulated by autoubiquitylation (Chen
et al., 2001; Nag et al., 2001). Additional Cul4-CRL complexes
(CRL4s) that mediate degradation of cancer relevant proteins
include tuberous sclerosis 2 (TSC2) by DDB1-Cul4FBW5, merlin
by DDB1-Cul4VprBP, ERa by DDB1-Cul4AhR, and c-Jun by
DDB1-Cul4hDET1-hCOP1 (for review, see Jackson and Xiong,
2009). An oncogenic role for Cul4 is further supported by the
fact Cul4A is located on 13q34, a region frequently amplified in
human tumors including breast cancer (Chen et al., 1998; Mel-
chor et al., 2009), and Cul4A deficient mice are resistant against
UV-induced skin tumors (Liu et al., 2009).
Cul5-Based CRLs
The suppressor of cytokine signaling (SOCS) family of proteins is
the substrate recognition component of Cul5-CRL complexes
(CRL5), and is comprised of 8members (SOCS1-7, CIS) contain-
ing an N-terminal domain, a SH2 domain and a C-terminal SOCS
box, which is composed of two regions; a BC box responsible for
binding Elongins BC and a Cul5 box that directs engagement to
Cul5 (Hilton, 1999). The SOCS box is also found in other proteins,
such as the SPRY (repeats in SplA/Ryanodine receptor) domain-172 Cancer Cell 19, February 15, 2011 ª2011 Elsevier Inc.containing SOCS box (SSB) protein family (Wang et al., 2005).
Notably, SOCS1 promotes proteasomal degradation of the
TEL-JAK2 fusion oncoprotein associated with leukemia
(Frantsve et al., 2001; Kamizono et al., 2001). Biallelic mutation
of SOCS1 has been found in mediastinal lymphoma and ectopic
expression of SOCS1 downregulates JAK2-STAT5 signaling
(Melzner et al., 2005). Additionally, the promoter of SOCS3
promoter has been shown to be hypermethylated in lung cancer
cell lines and primary tumor specimens resulting in reduced
SOCS3 protein expression and elevated pSTAT3 expression
(He et al., 2003). In addition, the human adenovirus serotype
5 (Ad5) products, E4orf6 and E1B55k, interact with CRL5 to
promote p53 degradation, which requires an intact NEDD8
pathway (Querido et al., 2001). Kaposi’s sarcoma-associated
herpes virus (KSHV)-encoded latency-associated nuclear
antigen (LANA) was found to use a similar mechanism to
promote degradation of the tumor suppressors VHL and p53 in
collaboration with CRL5 complex (Cai et al., 2006).
Cul7-Based CRLs and PARC
Fbxw8 is the only F-box protein known to interact with Cul7 and
unlike other cullins, Cul7 does not appear to be modified by
NEDD8 (Skaar et al., 2007). Nevertheless, Cul7 is overexpressed
in non-small cell lung carcinoma and regulates Cyclin D1, insulin
receptor substrate-1 (IRS-1), and p53 (Andrews et al., 2006; Kim
et al., 2007; Okabe et al., 2006; Xu et al., 2008). The Cul7
homolog PARC is modified by NEDD8 and appears to function
as a cytoplasmic anchor of p53 in neuroblastoma cells (Nikolaev
et al., 2003). However, the functional consequence of PARC
neddylation is yet to be determined.
MDM2, p53 Family, and Other NEDD8 Substrates
MDM2 is a RING finger E3 ligase amplified in human cancers that
promotes ubiquitylation and degradation of p53. Xirodimas et al.
(2004) demonstrated that MDM2 also promotes NEDD8 modifi-
cation of p53, which attenuates its transactivation function. Doh-
mesen et al. (2008) subsequently provided evidence that Tip60
acetyl transferase, a known regulator of the MDM2-p53 axis,
preferentially inhibited MDM2-mediated neddylation, but not
ubiquitylation, providing insight into the molecular mechanisms
differentially regulating these two processes. Interestingly,
NEDD8-interacting protein, NUB1, was shown to decrease p53
neddylation and preferentially stimulate p53 mono-ubiquityla-
tion, resulting in p53 nuclear export (Liu and Xirodimas, 2010).
The F-box protein, FBX011, was identified as a p53-interacting
protein that unexpectedly promoted p53 neddylation rather
than ubiquitylation to inhibit p53 transactivation function (Abida
et al., 2007). Notably, p53-NEDD8 fusion protein was shown to
differentially regulate transactivation of known p53 target genes
in comparison towild-type p53, suggesting that neddylationmay
play a role in determining p53-target gene specificity (Carter and
Vousden, 2008). MDM2 also promotes neddylation of the proa-
poptotic p53 family member, TAp73b, promoting accumulation
of NEDD8-modified TAp73b in the cytoplasm to inhibit its trans-
activation function (Watson et al., 2006).
MDM2 itself is subjected to NEDD8 modification (Xirodimas
et al., 2004), which was shown to significantly increase its
protein stability (Watson et al., 2010). Conversely, chemo-
therapy-induced NEDP1 was shown to promote MDM2 dened-
dylation and destabilization resulting in p53 activation (Watson
et al., 2010). p53 is also activated in the response to
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chemotherapy agent, Actinomycin D (ActD), due to ribosomal
protein-mediated inhibition of MDM20s E3 ligase activity (for
review, see Zhang and Lu, 2009). Ribosomal proteins were iden-
tified as NEDD8 substrates and NEDP1 was shown to regulate
both the stability and localization of ribosomal protein L11 (Xiro-
dimas et al., 2008). ActD-induced NEDP1 was associated with
the relocalization of L11 from the nucleolus to the nucleoplasm,
providing a signal for p53 activation (Sundqvist et al., 2009).
However, MDM2-mediated neddylation of L11 is also required
for its stabilization, illustrating a complex role of NEDD8 as
a regulator of p53 nucleolar stress signaling (Sun et al., 2010;
Sundqvist et al., 2009).
In addition, studies have also linked CRLs in the regulation of
the p53 family. In C. elegansmutants of the F-box protein, FSN-
1, were hypersensitive to ENU-induced germline apoptosis,
which was rescued by loss of the p53 homolog cep-1 (Gao
et al., 2008). The human ortholog of FSN-1 was later shown to
promote proteasomal degradation of p73 and the JFK F-box
protein was found to promote p53 degradation via SCF
complexes (Peschiaroli et al., 2009; Sun et al., 2009). Last,
SCFb-Trcp was recently shown to regulate the stability of MDM2
(Inuzuka et al., 2010).
In addition to cullins, VHL and the p53 family, the breast
cancer-associated protein 3 (BCA3) was identified as a NEDD8
substrate by Yeh and colleagues, which was shown to suppress
NF-kB-dependent transactivation through its ability to bind to
NF-kB subunit p65 and to recruit histone deacetylase SIRT1
(Gao et al., 2006). c-Cbl was shown to promote NEDD8 modifi-
cation of EGFR, which accelerated EGFR degradation via endo-
cytosis (Oved et al., 2006). Finally, proteomic approaches have
identified several potential NEDD8 substrates that play roles in
mRNA splicing, chromatin remodeling, DNA repair and replica-
tion (Jones et al., 2008; Xirodimas et al., 2008).
Targeting the NEDD8 Pathway: A New Approach
to Treat Cancer
Recently, the generation of MLN4924, a selective inhibitor of
general NEDD8 conjugation of substrates, was reported (Soucy
et al., 2009). MLN4924 is an adenosine sulfamate derivative and
the final product of an iterative medicinal chemistry effort
following the identification of its parent compound, N6-benzyl
adenosine, in a high throughput screen for NAE inhibitors.
MLN4924 is structurally related to AMP and forms a covalent
adduct with NEDD8, which is catalyzed by the NAE in a process
resembling the first NEDD8 adenylation step in the neddylation
cascade reaction. As described above, the transthiolation reac-
tion of UBL between E1-E2 enzymes occurs through a multistep
process. First, E1 mediates adenylation of UBL C-terminus and
the E1 catalytic cysteine subsequently attacks the adenylate to
form a thiolester bond. E1 adenylates an additional UBL mole-
cule and the occupancy of this second UBL-AMP promotes
the formation of thiolester bond between the first UBL loaded
and the E2. Interestingly, the formation of the NEDD8-
MLN4924 adducts occurs through a mechanism that takes
advantage of the reversibility of the E1 reaction cycle. Using
a number of approaches, Brownell et al. (2010) demonstrated
that MLN4924 adduct formation first requires ATP to form
NEDD8-AMP, followed by the formation of the NAE-NEDD8thiolester bond and the release of AMP. MLN4924 subsequently
binds the AMP-vacated nucleotide-binding site of NAE where its
sulfamate group acts as a nucleophile that attacks the thiolester
bond between NEDD8 and NAE subunit, Uba3, forming the
MLN4924 adduct. This study demonstrated that MLN4924 is
a competitive ATP inhibitor of NAE and showed that the
NEDD8-MLN4924 adduct once formed binds tightly and is
stable, thereby inhibiting further NAE enzymatic activity.
Studies in HCT-116 colorectal cells showed that addition of
MLN4924 inhibits the NEDD8 pathway as early as 5 min post-
treatment where MLN4924-NEDD8 adducts are observed, while
significantly decreasing Ubc12-NEDD8 thiolester-linked
complexes and neddylated cullins (Brownell et al., 2010). Treat-
ment of HCT-116 cells with MLN4924 resulted in S-phase
defects, DNA damage and subsequent apoptosis (Soucy et al.,
2009). Low doses of MLN4924 also inhibited tumor growth in
xenograft assays. Notably, MLN4924-mediated inhibition of
cullin neddylation resulted in increased total levels of the CRL
substrates CDT1, p27 and NRF2 (Soucy et al., 2009).
MLN4924 was recently tested in the treatment of acute
myeloid leukemia (AML) due to the fact that NEDD8 regulates
proteins, namely targets of CRLs, vital for AML cell survival
(Swords et al., 2010). MLN4924 was shown to have tumor
growth inhibiting properties in AML cells in vitro and in xenograft
assays, concomitant with increases in key CRL substrates,
including IkBa. AML cells appears to undergo increased
apoptosis in response to MLN4924 due to excessive generation
of ROSmediated by a decrease in NF-kB-mediated transactiva-
tion of target genes with antioxidant functions, such as super-
oxide dismutase 2 (SOD2) (Swords et al., 2010). Given the
number of oncoproteins and tumor suppressors that are targets
of NEDD8 conjugation cascade or CRLs whose activity is regu-
lated by NEDD8, MLN4924 may have promising anticancer
activity for cancers where perturbation of these pathways are
observed. Moreover, combination of NEDD8-mediated path-
ways rather than an individual pathway affected by MNL4924
should be carefully considered in predicting the utility of
MLN4924 treatment in the context of specific cancers.
Unquestionably, our discovery of the complexity in NEDD8-
dependent signaling pathways will continue to increase, which
will provide better understanding of cancer-specific biology
and afford new or perhaps unprecedented avenues of therapy.
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